文传商讯
Galderma Receives U.S. FDA Approval for Nemluvio (Nemolizumab) for Patients with Moderate-to-Severe
2024-12-17 22:11:08
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Pru
2024-12-14 03:09:54